Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 35, 2020 - Issue 1
Submit an article Journal homepage
3,745
Views
27
CrossRef citations to date
0
Altmetric
Research Paper

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)

Zhimin ZhangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Xinyue ChangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Chixiao ZhangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Shenxin ZengKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Meihao LiangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Zhen MaKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Zunyuan WangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaView further author information
,
Wenhai HuangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaCorrespondence[email protected]
View further author information
&
Zhengrong ShenKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, P. R. ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 1606-1615 | Received 10 Mar 2020, Accepted 27 Jul 2020, Published online: 11 Aug 2020

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Marta Pichlak, Tomasz Sobierajski, Katarzyna M. Błażewska & Edyta Gendaszewska-Darmach. (2023) Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Mandeep Rana, Amandeep Thakur, Charanjit Kaur, Chun-Hsu Pan, Sung-Bau Lee, Jing Ping Liou & Kunal Nepali. (2023) Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies. Expert Opinion on Drug Discovery 18:10, pages 1169-1193.
Read now
Mikhail Krasavin, Andrey Bubyrev, Alexander Kazantsev, Christopher Heim, Samuel Maiwald, Daniil Zhukovsky, Dmitry Dar’in, Marcus D. Hartmann & Alexander Bunev. (2022) Replacing the phthalimide core in thalidomide with benzotriazole. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 527-530.
Read now
Alexander Kazantsev & Mikhail Krasavin. (2022) Ligands for cereblon: 2017–2021 patent overview. Expert Opinion on Therapeutic Patents 32:2, pages 171-190.
Read now
Uday Kiran Velagapudi, Bhargav A. Patel, Xuwei Shao, Sanjai Kumar Pathak, Dana V. Ferraris & Tanaji T. Talele. (2021) Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). Expert Opinion on Therapeutic Patents 31:7, pages 609-623.
Read now

Articles from other publishers (22)

Yiquan Wu, Mingfei Wu, Xiaoli Zheng, Hengyuan Yu, Xinfei Mao, Yuyuan Jin, Yanhong Wang, Ao Pang, Jingyu Zhang, Shenxin Zeng, Tengfei Xu, Yong Chen, Bo Zhang, Nengming Lin, Haibin Dai, Yuwei Wang, Xiaojun Yao, Xiaowu Dong, Wenhai Huang & Jinxin Che. (2024) Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorganic Chemistry 142, pages 106952.
Crossref
Shenxin Zeng, Yingqiao Ye, Heye Xia, Jingli Min, Jiamei Xu, Zunyuan Wang, Youlu Pan, Xinglu Zhou & Wenhai Huang. (2023) Current advances and development strategies of orally bioavailable PROTACs. European Journal of Medicinal Chemistry 261, pages 115793.
Crossref
Amandeep Thakur, Mandeep Rana, Ritika, Jacob Mathew, Sanya Nepali, Chun-Hsu Pan, Jing Ping Liou & Kunal Nepali. (2023) Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship. Bioorganic Chemistry 141, pages 106893.
Crossref
Pingyuan Wang, Wen-Ting Zhu, Yajing Wang, Shan-Shan Song, Yong Xi, Xin-Ying Yang, Yan-Yan Shen, Yi Su, Yi-Ming Sun, Ying-Lei Gao, Yi Chen, Jian Ding, Ze-Hong Miao, Ao Zhang & Jin-Xue He. (2023) Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities. European Journal of Medicinal Chemistry 259, pages 115709.
Crossref
Yuting Sun, Hui Yang, Jiaqi Yuan, Limin Wang, Shanshan Song, Rongrong Chen, Xubin Bao, Li Jia, Tiantian Yang, Xiaofei Zhang, Qian He, Yong Gan, Zehong Miao, Jinxue He & Chunhao Yang. (2023) YCH1899, a Highly Effective Phthalazin-1(2 H )-one Derivative That Overcomes Resistance to Prior PARP Inhibitors . Journal of Medicinal Chemistry 66:17, pages 12284-12303.
Crossref
Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Ruolan Liu, Mei Yang, Edouard C. Nice, Huili Zhu & Canhua Huang. (2023) Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications. European Journal of Medicinal Chemistry 257, pages 115447.
Crossref
Hang Yang, Huihan Ai, Jialin Zhang, Jie Ma, Kangdong Liu & Zhi Li. (2023) UPS: Opportunities and challenges for gastric cancer treatment. Frontiers in Oncology 13.
Crossref
Chao Wang, Yujing Zhang, Junwen Deng, Bing Liang & Dongming Xing. (2023) Developments of PROTACs technology in immune-related diseases. European Journal of Medicinal Chemistry 249, pages 115127.
Crossref
Jie Zhang, Yuqi Gao, Zipeng Zhang, Jinbo Zhao, Wenshuang Jia, Chengcai Xia, Fugang Wang & Tingting Liu. (2022) Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment. Journal of Medicinal Chemistry 65:24, pages 16099-16127.
Crossref
Xiaopeng Peng, Wanyi Pan, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng & Jianjun Chen. (2022) Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Pharmacological Research 186, pages 106529.
Crossref
Ge Li, Shan-shan Lin, Ze-lei Yu, Xin-hua Wu, Jing-wen Liu, Gui-hui Tu, Quan-yu Liu, Yuan-ling Tang, Qing-na Jiang, Jian-hua Xu, Qing-ling Huang & Li-xian Wu. (2022) A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochemical Pharmacology 206, pages 115329.
Crossref
Xin Xu, Somaira Nowsheen & Min Deng. (2022) Exploring the DNA damage response pathway for synthetic lethality. Genome Instability & Disease 4:2, pages 98-120.
Crossref
Xin Wu, Yuan Zhang, Songbin Liu, Chang Liu, Guotao Tang, Xuan Cao, Xiaoyong Lei & Junmei Peng. (2022) Applications of “linkers” in fragment-based drug design. Bioorganic Chemistry 127, pages 105921.
Crossref
Chaoguo Cao, Ming He, Liguo Wang, Yuna He & Yu Rao. (2022) Chemistries of bifunctional PROTAC degraders. Chemical Society Reviews 51:16, pages 7066-7114.
Crossref
Dongha Kim & Hye Jin Nam. (2022) PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. International Journal of Molecular Sciences 23:15, pages 8412.
Crossref
Olga Bakulina, Alexander Sapegin, Alexander S. Bunev & Mikhail Krasavin. (2022) Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs). Mendeleev Communications 32:4, pages 419-432.
Crossref
Ming He, Chaoguo Cao, Zhihao Ni, Yongbo Liu, Peilu Song, Shuang Hao, Yuna He, Xiuyun Sun & Yu Rao. (2022) PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy 7:1.
Crossref
Maria Giulia Nizi, Mirko M. Maksimainen, Lari Lehtiö & Oriana Tabarrini. (2022) Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. Journal of Medicinal Chemistry 65:11, pages 7532-7560.
Crossref
Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen & Yong Peng. (2022) Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Molecular Cancer 21:1.
Crossref
Chao Wang, Yujing Zhang, Yudong Wu & Dongming Xing. (2021) Developments of CRBN-based PROTACs as potential therapeutic agents. European Journal of Medicinal Chemistry 225, pages 113749.
Crossref
Tim J. Wigle, Yue Ren, Jennifer R. Molina, Danielle J. Blackwell, Laurie B. Schenkel, Kerren K. Swinger, Kristy Kuplast‐Barr, Christina R. Majer, W. David Church, Alvin Z. Lu, Jason Mo, Ryan Abo, Anne Cheung, Bryan W. Dorsey, Mario Niepel, Nicholas R. Perl, Melissa M. Vasbinder, Heike Keilhack & Kevin W. Kuntz. (2021) Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule. ChemBioChem 22:12, pages 2107-2110.
Crossref
Chiho Kim, Chuo Chen & Yonghao Yu. (2021) Avoid the trap: Targeting PARP1 beyond human malignancy. Cell Chemical Biology 28:4, pages 456-462.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.